Osteoporosis

Seminars in Nuclear Medicine

Volumn 44, Issue 6, 2014, Pages 439-450

  Nanes, Mark S ^a   Kallen, Caleb B ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANABOLIC AGENT; BAZEDOXIFENE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; RALOXIFENE; VITAMIN D;

ARTICLE; BONE DENSITOMETRY; BONE DENSITY; CLINICAL ASSESSMENT; CLINICAL TRIAL (TOPIC); DIET SUPPLEMENTATION; EXERCISE; FOLLOW UP; FRAGILITY FRACTURE; HUMAN; LIFESTYLE MODIFICATION; META ANALYSIS (TOPIC); MUSCLE TRAINING; NUTRITIONAL SUPPORT; OSTEOPOROSIS; PHARMACEUTICAL CARE; POPULATION; POSTMENOPAUSE OSTEOPOROSIS; RISK ASSESSMENT; RISK FACTOR; SCREENING TEST; SECONDARY OSTEOPOROSIS; ANIMAL; PATHOPHYSIOLOGY;

ANIMALS; BONE DENSITY; FOLLOW-UP STUDIES; HUMANS; OSTEOPOROSIS;

EID: 84908280261     PISSN: 00012998     EISSN: 15584623     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2014.06.006     Document Type: Review

References (177)

1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy, March 7-29, 2000: Highlights of the conference South Med J 94 2001 569 573
2. M. Kleerekoper Osteoporosis overview C.J. Rosen, Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism 8th ed 2013 Wiley-Blackwell Ames, IA 345 347
3. V. Rabenda, J. Vanoverloop, and V. Fabri Low incidence of anti-osteoporosis treatment after hip fracture J Bone Joint Surg Am 90 2008 2142 2148
4. A.A. Luciano Osteoporosis: An update Hospital Physician, Obstetrics and Gynecology Board Review Manual 7 2001 16 24
5. A.C. Looker, E.S. Orwoll, and C.C. Johnston Jr Prevalence of low femoral bone density in older U.S. adults from NHANES III J Bone Miner Res 12 1997 1761 1768
6. D. Bliuc, N.D. Nguyen, and V.E. Milch Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women J Am Med Assoc 301 2009 513 521
7. D. Bliuc, N.D. Nguyen, and T.V. Nguyen Compound risk of high mortality following osteoporotic fracture and refracture in elderly women and men J Bone Miner Res 28 2013 2317 2324
8. C. Cooper The crippling consequences of fractures and their impact on quality of life Am J Med 103 1997 12S 17S [discussion 7S-9S]
9. S.A. Frost, N.D. Nguyen, and J.R. Center Excess mortality attributable to hip-fracture: A relative survival analysis Bone 56 2013 23 29
10. P.N. Kannegaard, S. van der Mark, and P. Eiken Excess mortality in men compared with women following a hip fracture. National analysis of comedications, comorbidity and survival Age Ageing 39 2010 203 209
11. T.K. Omsland, N. Emaus, and G.S. Tell Mortality following the first hip fracture in Norwegian women and men (1999-2008). A NOREPOS study Bone 63 2014 81 86
12. M. Piirtola, T. Vahlberg, and M. Lopponen Fractures as predictors of excess mortality in the aged-a population-based study with a 12-year follow-up Eur J Epidemiol 23 2008 747 755
13. L.J. Williams, M. Berk, and M.J. Henry Depression following fracture in women: A study of age-matched cohorts Br Med J Open 4 2014 e004226
14. S.C.E. Schuit, M. van der Klift, and A.E. Weel Fracture incidence and association with bone mineral density in elderly men and women: The Rotterdam Study Bone 34 2004 195 202
15. S.L. Hui, C.W. Slemenda, and C.C. Johnston Jr Age and bone mass as predictors of fracture in a prospective study J Clin Invest 81 1988 1804 1809
16. B. Dawson-Hughes, A.N. Tosteson, and L.J. Melton 3rd Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA Osteoporos Int 19 2008 449 458
17. A.N. Tosteson, L.J. Melton 3rd, and B. Dawson-Hughes Cost-effective osteoporosis treatment thresholds: The United States perspective Osteoporos Int 19 2008 437 447
18. J.L. Kelsey, W.S. Browner, and D.G. Seeley Risk factors for fractures of the distal forearm and proximal humerus. The Study of Osteoporotic Fractures Research Group Am J Epidemiol 135 1992 477 489
19. K. Cumming, G.E. Hoyle, and J.D. Hutchison Prevalence, incidence and etiology of hyponatremia in elderly patients with fragility fractures PloS One 9 2014 e88272
20. S. Kinsella, S. Moran, and M.O. Sullivan Hyponatremia independent of osteoporosis is associated with fracture occurrence Clin J Am Soc Nephrol 5 2010 275 280
21. H.S. Sandhu, E. Gilles, and M.V. DeVita Hyponatremia associated with large-bone fracture in elderly patients Int Urol Nephrol 41 2009 733 737
22. R. Tolouian, T. Alhamad, and M. Farazmand The correlation of hip fracture and hyponatremia in the elderly J Nephrol 25 2012 789 793
23. C.J. Zaino, A.V. Maheshwari, and D.S. Goldfarb Impact of mild chronic hyponatremia on falls, fractures, osteoporosis, and death Am J Orthop 42 2013 522 527
24. S.R. Venuturupalli, and W. Sacks Review of new guidelines for the management of glucocorticoid induced osteoporosis Curr Osteoporos Rep 11 2013 357 364
25. R. Rizzoli, J.D. Adachi, and C. Cooper Management of glucocorticoid-induced osteoporosis Calcif Tissue Int 91 2012 225 243
26. R.S. Weinstein Glucocorticoid-induced osteoporosis and osteonecrosis Endocrinol Metab Clin North Am 41 2012 595 611
27. N.B. Watts, R.A. Adler, and J.P. Bilezikian Osteoporosis in men: An Endocrine Society clinical practice guideline J Clin Endocrinol Metab 97 2012 1802 1822
28. A.C. Lassemillante, S.A. Doi, and J.D. Hooper Prevalence of osteoporosis in prostate cancer survivors: A meta-analysis Endocrine 45 2014 370 381
29. J.S. Walsh, and R. Eastell Osteoporosis in men Nat Rev Endocrinol 9 2013 637 645
30. M.L. Gourlay, J.S. Preisser, and L.Y. Lui BMD screening in older women: Initial measurement and testing interval J Bone Miner Res 27 2012 743 746
31. F.L. Levy, B. Adams-Huet, and C.Y. Pak Ambulatory evaluation of nephrolithiasis: An update of a 1980 protocol Am J Med 98 1995 50 59
32. C. Tannenbaum, J. Clark, and K. Schwartzman Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women J Clin Endocrinol Metab 87 2002 4431 4437
33. F. Iqbal, J. Michaelson, and L. Thaler Declining bone mass in men with chronic pulmonary disease: Contribution of glucocorticoid treatment, body mass index, and gonadal function Chest 116 1999 1616 1624
34. P. Von Heideken Wagert, H. Littbrand, and A. Johansson Jumping exercises with and without raloxifene treatment in healthy elderly women J Bone Miner Metab 20 2002 376 382
35. T. Suzuki, H. Kim, and H. Yoshida Randomized controlled trial of exercise intervention for the prevention of falls in community-dwelling elderly Japanese women J Bone Miner Metab 22 2004 602 611
36. I. Bergstrom, B. Landgren, and J. Brinck Physical training preserves bone mineral density in postmenopausal women with forearm fractures and low bone mineral density Osteoporos Int 19 2008 177 183
37. M.R. Hendriks, M.H. Bleijlevens, and J.C. van Haastregt Lack of effectiveness of a multidisciplinary fall-prevention program in elderly people at risk: A randomized, controlled trial J Am Geriatr Soc 56 2008 1390 1397
38. S.R. Hourigan, J.C. Nitz, and S.G. Brauer Positive effects of exercise on falls and fracture risk in osteopenic women Osteoporos Int 19 2008 1077 1086
39. W. Kemmler, S. von Stengel, and K. Engelke Exercise effects on bone mineral density, falls, coronary risk factors, and health care costs in older women: The randomized controlled senior fitness and prevention (SEFIP) study Arch Intern Med 170 2010 179 185
40. K. Uusi-Rasi, P. Kannus, and S. Karinkanta Study protocol for prevention of falls: A randomized controlled trial of effects of vitamin D and exercise on falls prevention BMC Geriatr 12 2012 12
41. A. Trombetti, M. Hars, and F. Herrmann Effect of a multifactorial fall-and-fracture risk assessment and management program on gait and balance performances and disability in hospitalized older adults: A controlled study Osteoporos Int 24 2013 867 876
42. H.A. Bischoff-Ferrari, J.R. Rees, and M.V. Grau Effect of calcium supplementation on fracture risk: A double-blind randomized controlled trial Am J Clin Nutr 87 2008 1945 1951
43. R.D. Jackson, A.Z. LaCroix, and M. Gass Calcium plus vitamin D supplementation and the risk of fractures N Engl J Med 354 2006 669 683
44. H.A. Bischoff-Ferrari, W.C. Willett, and J.B. Wong Fracture prevention with vitamin D supplementation: A meta-analysis of randomized controlled trials J Am Med Assoc 293 2005 2257 2264
45. H. Lilliu, R. Pamphile, and M.C. Chapuy Calcium-vitamin D3 supplementation is cost-effective in hip fractures prevention Maturitas 44 2003 299 305
46. I.R. Reid, R.W. Ames, and M.C. Evans Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women: A randomized controlled trial Am J Med 98 1995 331 335
47. B. Dawson-Hughes, and H.A. Bischoff-Ferrari Therapy of osteoporosis with calcium and vitamin D J Bone Miner Res 22 suppl 2 2007 V59 V63
48. H.A. Bischoff-Ferrari, E.J. Orav, and B. Dawson-Hughes Effect of cholecalciferol plus calcium on falling in ambulatory older men and women: A 3-year randomized controlled trial Arch Intern Med 166 2006 424 430
49. M.J. Bolland, A. Avenell, and J.A. Baron Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: Meta-analysis Br Med J 341 2010 c3691
50. M.J. Bolland, P.A. Barber, and R.N. Doughty Vascular events in healthy older women receiving calcium supplementation: Randomised controlled trial Br Med J 336 2008 262 266
51. M.J. Bolland, A. Grey, and A. Avenell Calcium supplements with or without vitamin D and risk of cardiovascular events: Reanalysis of the Women's Health Initiative limited access dataset and meta-analysis Br Med J 342 2011 d2040
52. M.J. Bolland, A. Grey, and I.R. Reid Calcium supplements and cardiovascular risk J Bone Miner Res 26 899 2011 900 901 [author reply]
53. J.R. Lewis, K. Zhu, and R.L. Prince Adverse events from calcium supplementation: Relationship to errors in myocardial infarction self-reporting in randomized controlled trials of calcium supplementation J Bone Miner Res 27 2012 719 722
54. J.R. Lewis, K. Zhu, and P.L. Thompson The effects of 3 years of calcium supplementation on common carotid artery intimal medial thickness and carotid atherosclerosis in older women: An ancillary study of the CAIFOS randomized controlled trial J Bone Miner Res 29 2014 534 541
55. L.T. Radford, M.J. Bolland, and G.D. Gamble Subgroup analysis for the risk of cardiovascular disease with calcium supplements Bonekey Rep 2 2013 293
56. I.R. Reid, and M.J. Bolland Does widespread calcium supplementation pose cardiovascular risk? Yes: The potential risk is a concern Am Fam Physician 87 2013 [Online]
57. I.R. Reid, M.J. Bolland, and A. Avenell Cardiovascular effects of calcium supplementation Osteoporos Int 22 2011 1649 1658
58. I.R. Reid, M.J. Bolland, and P.N. Sambrook Calcium supplementation: Balancing the cardiovascular risks Maturitas 69 2011 289 295
59. D.K. Liang, X.J. Bai, and B. Wu Associations between bone mineral density and subclinical atherosclerosis: A cross-sectional study of a Chinese population J Clin Endocrinol Metab 99 2014 469 477
60. C.E. Powe, M.K. Evans, and J. Wenger Vitamin D-binding protein and vitamin D status of black Americans and white Americans N Engl J Med 369 2013 1991 2000
61. A.H. Warriner, and K.G. Saag Osteoporosis diagnosis and medical treatment Orthop Clin North Am 44 2013 125 135
62. E.F. Eriksen, A. Diez-Perez, and S. Boonen Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: A systematic review Bone 58 2014 126 135
63. E. Canalis, A. Giustina, and J.P. Bilezikian Mechanisms of anabolic therapies for osteoporosis N Engl J Med 357 2007 905 916
64. R.M. Neer, C.D. Arnaud, and J.R. Zanchetta Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis N Engl J Med 344 2001 1434 1441
65. H. Bone Future directions in osteoporosis therapeutics Endocrinol Metab Clin North Am 41 2012 655 661
66. T.J. Martin Bone biology and anabolic therapies for bone: Current status and future prospects J Bone Metab 21 2014 8 20
67. S.H. Tella, and J.C. Gallagher Prevention and treatment of postmenopausal osteoporosis J Steroid Biochem Mol Biol 2013
68. D.M. Black, S.R. Cummings, and D.B. Karpf Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group Lancet 348 1996 1535 1541
69. S.R. Cummings, D.M. Black, and D.E. Thompson Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial J Am Med Assoc 280 1998 2077 2082
70. S.T. Harris, N.B. Watts, and H.K. Genant Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group J Am Med Assoc 282 1999 1344 1352
71. M.R. McClung, P. Geusens, and P.D. Miller Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group N Engl J Med 344 2001 333 340
72. A. Cranney, G. Guyatt, and L. Griffith Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis Endocr Rev 23 2002 570 578
73. C.H. Chesnut, M.P. Ettinger, and P.D. Miller Ibandronate produces significant, similar antifracture efficacy in North American and European women: New clinical findings from BONE Curr Med Res Opin 21 2005 391 401
74. K.W. Lyles, C.S. Colon-Emeric, and J.S. Magaziner Zoledronic acid in reducing clinical fracture and mortality after hip fracture N Engl J Med 357 2007 [nihpa40967]
75. D.M. Black, P.D. Delmas, and R. Eastell Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis N Engl J Med 356 2007 1809 1822
76. R. Eastell, J.S. Walsh, and N.B. Watts Bisphosphonates for postmenopausal osteoporosis Bone 49 2011 82 88
77. N.B. Watts, and D.L. Diab Long-term use of bisphosphonates in osteoporosis J Clin Endocrinol Metab 95 2010 1555 1565
78. J.P. Bilezikian Osteonecrosis of the jaw - Do bisphosphonates pose a risk? N Engl J Med 355 2006 2278 2281
79. E. Chamizo Carmona, A. Gallego Flores, and E. Loza Santamaria Systematic literature review of bisphosphonates and osteonecrosis of the jaw in patients with osteoporosis Reumatol Clin 9 2013 172 177
80. S. Khosla, D. Burr, and J. Cauley Bisphosphonate-associated osteonecrosis of the jaw: Report of a task force of the American Society for Bone and Mineral Research J Bone Miner Res 22 2007 1479 1491
81. L. Gedmintas, D.H. Solomon, and S.C. Kim Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: A systematic review and meta-analysis J Bone Miner Res 28 2013 1729 1737
82. S. Khosla, J.P. Bilezikian, and D.W. Dempster Benefits and risks of bisphosphonate therapy for osteoporosis J Clin Endocrinol Metab 97 2012 2272 2282
83. B. Ettinger, D.M. Black, and B.H. Mitlak Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators J Am Med Assoc 282 1999 637 645
84. P.D. Delmas, K.E. Ensrud, and J.D. Adachi Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: Four-year results from a randomized clinical trial J Clin Endocrinol Metab 87 2002 3609 3617
85. P.D. Miller, A.A. Chines, and C. Christiansen Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study J Bone Miner Res 23 2008 525 535
86. T.J. de Villiers, A.A. Chines, and S. Palacios Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: Results of a 5-year, randomized, placebo-controlled phase 3 trial Osteoporos Int 22 2011 567 576
87. J.A. Kanis, H. Johansson, and A. Oden Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX Bone 44 2009 1049 1054
88. C.C. Mok, K.Y. Ying, and C.H. To Raloxifene for prevention of glucocorticoid-induced bone loss: A 12-month randomised double-blinded placebo-controlled trial Ann Rheum Dis 70 2011 778 784
89. E.S. Siris, S.T. Harris, and R. Eastell Skeletal effects of raloxifene after 8 years: Results from the continuing outcomes relevant to Evista (CORE) study J Bone Miner Res 20 2005 1514 1524
90. S. Martino, J.A. Cauley, and E. Barrett-Connor Continuing outcomes relevant to Evista: Breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene J Natl Cancer Inst 96 2004 1751 1761
91. E. Barrett-Connor, L. Mosca, and P. Collins Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women N Engl J Med 355 2006 125 137
92. V.G. Vogel, J.P. Costantino, and D.L. Wickerham Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial J Am Med Assoc 295 2006 2727 2741
93. L. Mosca, D. Grady, and E. Barrett-Connor Effect of raloxifene on stroke and venous thromboembolism according to subgroups in postmenopausal women at increased risk of coronary heart disease Stroke 40 2009 147 155
94. K. Ensrud, A.R. Genazzani, and M.J. Geiger Effect of raloxifene on cardiovascular adverse events in postmenopausal women with osteoporosis Am J Cardiol 97 2006 520 527
95. J.E. Rossouw, G.L. Anderson, and R.L. Prentice Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial J Am Med Assoc 288 2002 321 333
96. C.H. Chesnut 3rd, S. Silverman, and K. Andriano A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The prevent recurrence of osteoporotic fractures study. PROOF Study Group Am J Med 109 2000 267 276
97. P.J. Bekker, D.L. Holloway, and A.S. Rasmussen A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women J Bone Miner Res 19 2004 1059 1066
98. P.J. Bekker, D.L. Holloway, and A.S. Rasmussen A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. 2004 J Bone Miner Res 20 2005 2275 2282
99. H.G. Bone, M.A. Bolognese, and C.K. Yuen Effects of denosumab on bone mineral density and bone turnover in postmenopausal women J Clin Endocrinol Metab 93 2008 2149 2157
100. H.G. Bone, R. Chapurlat, and M.L. Brandi The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: Results from the FREEDOM extension J Clin Endocrinol Metab 98 2013 4483 4492
101. S.R. Cummings, J. San Martin, and M.R. McClung Denosumab for prevention of fractures in postmenopausal women with osteoporosis N Engl J Med 361 2009 756 765
102. G.K. Ellis, H.G. Bone, and R. Chlebowski Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: Subgroup analyses of a phase 3 study Breast Cancer Res Treat 118 2009 81 87
103. S. Papapoulos, R. Chapurlat, and C. Libanati Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension J Bone Miner Res 27 2012 694 701
104. J.P. Brown, I.R. Reid, and R.B. Wagman Effects of up to 5 years of denosumab treatment on bone histology and histomorphometry: The FREEDOM Study Extension J Bone Miner Res 29 2014 2051 2056
105. S. Adami, C. Libanati, and S. Boonen Denosumab treatment in postmenopausal women with osteoporosis does not interfere with fracture-healing: Results from the FREEDOM trial J Bone Joint Surg Am 94 2012 2113 2119
106. M.S. Nanes Preventing metastases to bone: Denosumab or bisphosphonates? J Bone Miner Res 25 2010 437 439
107. P.D. Miller, M.A. Bolognese, and E.M. Lewiecki Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial Bone 43 2008 222 229
108. K.A. Toulis, and A.D. Anastasilakis Increased risk of serious infections in women with osteopenia or osteoporosis treated with denosumab Osteoporos Int 21 2010 1963 1964
109. N.B. Watts, C. Roux, and J.F. Modlin Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: Coincidence or causal association? Osteoporos Int 23 2012 327 337
110. S.L. Greenspan, H.G. Bone, and M.P. Ettinger Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: A randomized trial Ann Intern Med 146 2007 326 339
111. R. Lindsay, P. Miller, and G. Pohl Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosis Osteoporos Int 20 2009 943 948
112. D.M. Black, J.P. Bilezikian, and K.E. Ensrud One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis N Engl J Med 353 2005 555 565
113. D.M. Black, S.L. Greenspan, and K.E. Ensrud The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis N Engl J Med 349 2003 1207 1215
114. B. Ettinger, J. San Martin, and G. Crans Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate J Bone Miner Res 19 2004 745 751
115. R.P. Handler Prior bisphosphonate therapy of osteoporosis attenuates and blocks response to subsequent parathyroid hormone J Clin Rheumatol 14 2008 122 124
116. B.M. Obermayer-Pietsch, F. Marin, and E.V. McCloskey Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment J Bone Miner Res 23 2008 1591 1600
117. S. Boonen, F. Marin, and B. Obermayer-Pietsch Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis J Clin Endocrinol Metab 93 2008 852 860
118. E.T. Middleton, S.A. Steel, and S.M. Doherty The effect of prior bisphosphonate exposure on the treatment response to teriparatide in clinical practice Calcif Tissue Int 81 2007 335 340
119. P.D. Miller, P.D. Delmas, and R. Lindsay Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate J Clin Endocrinol Metab 93 2008 3785 3793
120. P.D. Miller, J.P. Bilezikian, and M. Diaz-Curiel Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide J Clin Endocrinol Metab 92 2007 3535 3541
121. F. Cosman, J.W. Nieves, and M. Zion Retreatment with teriparatide one year after the first teriparatide course in patients on continued long-term alendronate J Bone Miner Res 24 2009 1110 1115
122. S. Adami, J. San Martin, and M. Munoz-Torres Effect of raloxifene after recombinant teriparatide [hPTH (1-34)] treatment in postmenopausal women with osteoporosis Osteoporos Int 19 2008 87 94
123. N.E. Cusano, and J.P. Bilezikian Combination anabolic and antiresorptive therapy for osteoporosis Endocrinol Metab Clin North Am 41 2012 643 654
124. R. Eastell, T. Nickelsen, and F. Marin Sequential treatment of severe postmenopausal osteoporosis after teriparatide: Final results of the randomized, controlled European Study of Forsteo (EUROFORS) J Bone Miner Res 24 2009 726 736
125. A.L. Schafer, D.E. Sellmeyer, and L. Palermo Six months of parathyroid hormone (1-84) administered concurrently versus sequentially with monthly ibandronate over two years: The PTH and ibandronate combination study (PICS) randomized trial J Clin Endocrinol Metab 97 2012 3522 3529
126. C.A. O'Brien, T. Nakashima, and H. Takayanagi Osteocyte control of osteoclastogenesis Bone 54 2013 258 263
127. D.L. Lacey, W.J. Boyle, and W.S. Simonet Bench to bedside: Elucidation of the OPG-RANK-RANKL pathway and the development of denosumab Nat Rev Drug Discov 11 2012 401 419
128. M. Rossini, D. Gatti, and S. Adami Involvement of WNT/beta-catenin signaling in the treatment of osteoporosis Calcif Tissue Int 93 2013 121 132
129. E. Gazzerro, and E. Canalis Bone morphogenetic proteins and their antagonists Rev Endocr Metab Disord 7 2006 51 65
130. A. Giustina, G. Mazziotti, and E. Canalis Growth hormone, insulin-like growth factors, and the skeleton Endocr Rev 29 2008 535 559
131. T.L. McCarthy, M. Centrella, and E. Canalis Regulatory effects of insulin-like growth factors I and II on bone collagen synthesis in rat calvarial cultures Endocrinology 124 1989 301 309
132. J. Rubin, C.L. Ackert-Bicknell, and L. Zhu IGF-I regulates osteoprotegerin (OPG) and receptor activator of nuclear factor-kappaB ligand in vitro and OPG in vivo J Clin Endocrinol Metab 87 2002 4273 4279
133. E. Canalis, V. Deregowski, and R.C. Pereira Signals that determine the fate of osteoblastic cells J Endocrinol Invest 28 2005 3 7
134. A.M. Delany, J.M. Pash, and E. Canalis Cellular and clinical perspectives on skeletal insulin-like growth factor I J Cell Biochem 55 1994 328 333
135. Y. Kawano, and R. Kypta Secreted antagonists of the Wnt signalling pathway J Cell Sci 116 2003 2627 2634
136. P.V. Bodine, and B.S. Komm Wnt signaling and osteoblastogenesis Rev Endocr Metab Disord 7 2006 33 39
137. V. Deregowski, E. Gazzerro, and L. Priest Notch 1 overexpression inhibits osteoblastogenesis by suppressing Wnt/beta-catenin but not bone morphogenetic protein signaling J Biol Chem 281 2006 6203 6210
138. S. Rydziel, and E. Canalis Cortisol represses insulin-like growth factor II receptor transcription in skeletal cell cultures Endocrinology 136 1995 4254 4260
139. X. Li, Y. Zhang, and H. Kang Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling J Biol Chem 280 2005 19883 19887
140. M.R. McClung, A. Grauer, and S. Boonen Romosozumab in postmenopausal women with low bone mineral density N Engl J Med 370 2014 412 420
141. M.S. Anderson, I.N. Gendrano, and C. Liu Odanacatib, a selective cathepsin K inhibitor, demonstrates comparable pharmacodynamics and pharmacokinetics in older men and postmenopausal women J Clin Endocrinol Metab 99 2014 552 560
142. H.G. Bone, M.R. McClung, and C. Roux Odanacatib, a cathepsin-K inhibitor for osteoporosis: A two-year study in postmenopausal women with low bone density J Bone Miner Res 25 2010 937 947
143. K. Brixen, R. Chapurlat, and A.M. Cheung Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: A randomized trial J Clin Endocrinol Metab 98 2013 571 580
144. T. Cusick, C.M. Chen, and B.L. Pennypacker Odanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkey J Bone Miner Res 27 2012 524 537
145. J.A. Eisman, H.G. Bone, and D.J. Hosking Odanacatib in the treatment of postmenopausal women with low bone mineral density: Three-year continued therapy and resolution of effect J Bone Miner Res 26 2011 242 251
146. B. Langdahl, N. Binkley, and H. Bone Odanacatib in the treatment of postmenopausal women with low bone mineral density: Five years of continued therapy in a phase 2 study J Bone Miner Res 27 2012 2251 2258
147. T. Nakamura, M. Shiraki, and M. Fukunaga Effect of the cathepsin K inhibitor odanacatib administered once weekly on bone mineral density in Japanese patients with osteoporosis - A double-blind, randomized, dose-finding study Osteoporos Int 25 2014 367 376
148. S.A. Stoch, S. Zajic, and J. Stone Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: Two double-blind, randomized, placebo-controlled phase I studies Clin Pharmacol Ther 86 2009 175 182
149. E. Canalis, M. Centrella, and W. Burch Insulin-like growth factor I mediates selective anabolic effects of parathyroid hormone in bone cultures J Clin Invest 83 1989 60 65
150. N. Miyakoshi, Y. Kasukawa, and T.A. Linkhart Evidence that anabolic effects of PTH on bone require IGF-I in growing mice Endocrinology 142 2001 4349 4356
151. G. Zhao, M.C. Monier-Faugere, and M.C. Langub Targeted overexpression of insulin-like growth factor I to osteoblasts of transgenic mice: Increased trabecular bone volume without increased osteoblast proliferation Endocrinology 141 2000 2674 2682
152. S. Grinspoon, L. Thomas, and K. Miller Effects of recombinant human IGF-I and oral contraceptive administration on bone density in anorexia nervosa J Clin Endocrinol Metab 87 2002 2883 2891
153. M. Misra, J. McGrane, and K.K. Miller Effects of rhIGF-1 administration on surrogate markers of bone turnover in adolescents with anorexia nervosa Bone 45 2009 493 498
154. N.R. Biermasz, N.A. Hamdy, and A.M. Pereira Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: A seven-year follow-up study Clin Endocrinol (Oxf) 60 2004 568 575
155. G. Finkenstedt, R.W. Gasser, and G. Hofle Effects of growth hormone (GH) replacement on bone metabolism and mineral density in adult onset of GH deficiency: Results of a double-blind placebo-controlled study with open follow-up Eur J Endocrinol 136 1997 282 289
156. L.J. Ghiron, J.L. Thompson, and L. Holloway Effects of recombinant insulin-like growth factor-I and growth hormone on bone turnover in elderly women J Bone Miner Res 10 1995 1844 1852
157. P. Gillberg, H. Mallmin, and M. Petren-Mallmin Two years of treatment with recombinant human growth hormone increases bone mineral density in men with idiopathic osteoporosis J Clin Endocrinol Metab 87 2002 4900 4906
158. D.S. Hardin, C. Ahn, and C. Prestidge Growth hormone improves bone mineral content in children with cystic fibrosis J Pediatr Endocrinol Metab 18 2005 589 595
159. M. Kuzma, Z. Homerova, and A. Dlesk Effect of growth hormone on bone status in growth hormone-deficient adults Bratisl Lek Listy 114 2013 689 695
160. K. Landin-Wilhelmsen, A. Nilsson, and I. Bosaeus Growth hormone increases bone mineral content in postmenopausal osteoporosis: A randomized placebo-controlled trial J Bone Miner Res 18 2003 393 405
161. M. Saaf, A. Hilding, and M. Thoren Growth hormone treatment of osteoporotic postmenopausal women - A one-year placebo-controlled study Eur J Endocrinol 140 1999 390 399
162. T. Sugimoto, H. Kaji, and D. Nakaoka Effect of low-dose of recombinant human growth hormone on bone metabolism in elderly women with osteoporosis Eur J Endocrinol 147 2002 339 348
163. F. Tanriverdi, K. Unluhizarci, and M. Kula Effects of 18-month of growth hormone (GH) replacement therapy in patients with Sheehan's syndrome Growth Horm IGF Res 15 2005 231 237
164. B.L. Riggs Treatment of osteoporosis with sodium fluoride or parathyroid hormone Am J Med 91 1991 37S 41S
165. B.L. Riggs, S.F. Hodgson, and D.L. Hoffman Treatment of primary osteoporosis with fluoride and calcium. Clinical tolerance and fracture occurrence J Am Med Assoc 243 1980 446 449
166. B.L. Riggs, S.F. Hodgson, and W.M. O'Fallon Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis N Engl J Med 322 1990 802 809
167. B.L. Riggs, W.M. O'Fallon, and A. Lane Clinical trial of fluoride therapy in postmenopausal osteoporotic women: Extended observations and additional analysis J Bone Miner Res 9 1994 265 275
168. B.L. Riggs, E. Seeman, and S.F. Hodgson Effect of the fluoride/calcium regimen on vertebral fracture occurrence in postmenopausal osteoporosis. Comparison with conventional therapy N Engl J Med 306 1982 446 450
169. P. Vestergaard, N.R. Jorgensen, and P. Schwarz Effects of treatment with fluoride on bone mineral density and fracture risk - A meta-analysis Osteoporos Int 19 2008 257 268
170. A. Grey, S. Garg, and M. Dray Low-dose fluoride in postmenopausal women: A randomized controlled trial J Clin Endocrinol Metab 98 2013 2301 2307
171. S. O'Donnell, A. Cranney, and G.A. Wells Strontium ranelate for preventing and treating postmenopausal osteoporosis Cochrane Database Syst Rev 3 2006 CD005326
172. P.J. Meunier, C. Roux, and E. Seeman The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis N Engl J Med 350 2004 459 468
173. C. Roux Strontium ranelate: Short- and long-term benefits for post-menopausal women with osteoporosis Rheumatology (Oxford) 47 suppl 4 2008 iv20 iv22
174. C. Roux, J.Y. Reginster, and J. Fechtenbaum Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors J Bone Miner Res 21 2006 536 542
175. M. Audran, F.J. Jakob, and S. Palacios A large prospective European cohort study of patients treated with strontium ranelate and followed up over 3 years Rheumatol Int 33 2013 2231 2239
176. J.A. Kanis, H. Johansson, and A. Oden A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX(®) Osteoporos Int 22 2011 2347 2355
177. R. Rizzoli, R.D. Chapurlat, and J.M. Laroche Effects of strontium ranelate and alendronate on bone microstructure in women with osteoporosis. Results of a 2-year study Osteoporos Int 23 2012 305 315